NASDAQ | ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset.
The fund is non-diversified.
Top 14 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| NVO | Novo Nordisk A/S | Healthcare | Biotechnology | 20.43% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 19.98% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 4.15% |
| ZEAL | Zealand Pharma A/S | Healthcare | Biotechnology | 3.91% |
| 1801 | Innovent Biologics Inc | Healthcare | Biotechnology | 3.58% |
| AZN | AstraZeneca PLC ADR | Healthcare | Drug Manufacturers - General | 3.54% |
| ROG | Roche Holding AG | Healthcare | Drug Manufacturers - General | 3.50% |
| TERN | Terns Pharmaceuticals Inc | Healthcare | Biotechnology | 3.32% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 3.27% |
| ALT | Altimmune Inc | Healthcare | Biotechnology | 3.22% |
| PFE | Pfizer Inc | Healthcare | Drug Manufacturers - General | 3.18% |
| GPCR | Structure Therapeutics Inc. American Depositary Shares | Healthcare | Biotechnology | 3.14% |
| VKTX | Viking Therapeutics Inc | Healthcare | Biotechnology | 3.02% |
| 128940 | Hanmi Pharm Co Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | 2.83% |